Information from Industry - Sponsored Supplement

Forget Fibrates for Cardiovascular Risk Reduction: Commentary on the Failure and Implications of the PROMINENT Trial

Developed under the direction and sponsorship of Amarin Pharma, Inc.

 

In this supplement to Family Medicine, Charles P Vega, MD, and Pamela R Kushner, MD, discuss failure of the PROMINENT trial and implications for use of fibrates to reduce cardiovascular risk.

 

Read More 

 

 

 

 

Recommended Reading

Personalizing treatment plans for older patients with T2D
MDedge Family Medicine
Long-COVID patients respond differently to COVID vaccines
MDedge Family Medicine
Hepatitis A is on the rise: What FPs can do
MDedge Family Medicine
Can an endoscopic procedure treat type 2 diabetes?
MDedge Family Medicine
Remote weight monitoring minimizes office visits for newborns
MDedge Family Medicine
New blood pressure thresholds: How do they affect the evaluation and treatment of hypertension?
MDedge Family Medicine
FMT in a pill: FDA approves second product to prevent C. diff recurrence
MDedge Family Medicine
Gut microbiome may guide personalized heart failure therapy
MDedge Family Medicine
Experts outline comprehensive preeclampsia prevention strategy
MDedge Family Medicine
Cautious optimism for new Alzheimer’s disease biomarkers and treatments, expert says
MDedge Family Medicine